user Sign In

QYResearch Account

Manage your Account and Access Personalized Content.

Sign in

Create Account with us

Manage your Account and Access Personalized Content.

Sign Up
       
  
×

Global Transforming Growth Factor Beta 1 Market Professional Survey Report 2019

Published Date: 2019-01-11   |   Pages: 107   |   Tables: 125   | Report Id: 920369   | Hits: 5 |   Pharma & Healthcare



Transforming growth factor beta 1 or TGF-β1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, and apoptosis. In humans, TGF-β1 is encoded by the TGFB1 gene

North America is the largest consumption place, with a consumption market share nearly 61.5% in 2017. Following North America, Asia-Pacific and Europe is the second two largest consumption places with the consumption market share of 18% and 17%, respectively.

The global Transforming Growth Factor Beta 1 market was valued at 1050 million US$ in 2018 and will reach 2190 million US$ by the end of 2025, growing at a CAGR of 11.1% during 2019-2025.

This report focuses on Transforming Growth Factor Beta 1 volume and value at global level, regional level and company level. From a global perspective, this report represents overall Transforming Growth Factor Beta 1 market size by analyzing historical data and future prospect.

Regionally, this report categorizes the production, apparent consumption, export and import of Transforming Growth Factor Beta 1 in North America, Europe, China, Japan, Southeast Asia and India.

For each manufacturer covered, this report analyzes their Transforming Growth Factor Beta 1 manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:

Roche

Shionogi Ltd

Acceleron Pharma Inc

Genzyme Corp

Isarna Therapeutics GmbH

Scholar Rock

Sirnaomics Inc

Eli Lilly and Co

Formation Biologics Inc

Novartis AG

Segment by Regions

North America

Europe

China

Japan

Southeast Asia

India

Segment by Type

Pirfenidone

Galunisertib

Others

Segment by Application

IPF

Cancer

Others

Licenses Type

Only one user can access the report
Multiple users can access the report

Why QYR

 Fastest report delivery service
 More than 10 years of vast experience
 Operational for 24 * 7 & 365 days
 In-depth and comprehensive analysis
 Excellent after sales support
 Owns large database

Need Help ?

QYR Clients

More Clients...